Cancer molecular-target therapy
- 최초 등록일
- 2011.01.05
- 최종 저작일
- 2010.12
- 39페이지/
한컴오피스
- 가격 1,000원
![할인쿠폰받기](/images/v4/document/ico_det_coupon.gif)
소개글
서울대학교 약학대학 DDS(Drug delivery sysytem)수업자료입니다.
molecular target therapy를 이용하여 표적항암치료제를 개발하기위한 현재까지의 연구방향들이 작성되어있으며 지금까지의 연구들의 문제점과 앞으로의 연구개발방향에 대한 의견이 작성되어있습니다.
목차
Contents
1. EGFR
a. MAbs for EGFR
b. Small chemical inhibitors for EGFR
2. VEGF-R
a. MAbs for EGFR
b. Small chemical inhibitors for EGFR
3. Discussion
a. Just 1 drug is not enough
b. Specific for specific cancer
c. side effect
4. Solution
a. Passive targeting
b. Active targeting
본문내용
1. EGFR
EGFR(Epidermal growth factor receptor) is one of the receptors that included in ERBB family of receptor tyrosine kinases. It is also closely related with HER2 (ERBB2), HER3 (ERBB3) and HER4 (ERBB4). Giampaolo Tortora, A Novel Approach in the Treatment of Cancer: Targeting the Epidermal Growth Factor Receptor, Clinical Cancer Research,Vol. 7, 29582970, October 2001
EGFR is consisted of extra-cellular part of lignad binding, transmembrane domain and intra-cellular domain. Specially intra-cellular domain has own function that phosphorylation of tyrosine so we called that domain as a tyrosine kinase domain. After lignad binding to the monomer EGFR two receptors of EGFR are combined together and we called this process about dimerization. Dimerization allowed to tyrosine kinase activation so many of ATP is used for autophosphorylation. Autophosphorylation means that Addition of a phosphate to a protein kinase by virtue of its own enzymic activity. After phosphorylation it trigger many signals to down streaam. EGFR is expressed in various solid tumours, including 40~80% of NSCLCs(Non small cell lung cancer), providing a strong rationale for testing EGFR inhibitors in patients with such tumors(Table 1.)
참고 자료
1. Giampaolo Tortora, A Novel Approach in the Treatment of Cancer: Targeting the Epidermal Growth Factor Receptor, Clinical Cancer Research,Vol. 7, 2958–2970, October 2001
이하 refference 52개 자료